Day 2 - Friday 24th May 2024
10th RWE, Market Access, Pricing & Reimbursement Global Congress 2024 Europe
Trends and Strategies to Optimise Value and Patient Access
Hilton London Kensington, London, UK
Josie Godfrey, Co-Founder and CEO, Realise Advocacy
CHALLENGES & OPPORTUNITIES
- Advantages of market access teams in payer relationship
- Payer evidence requirement in early development
- Best practices to obtain better pricing and reimbursement
- Strategies to improve a better payer relationship
Moderator:
Alexander Bastian, VP, Value & Market Access, AM-Pharma
Panelist: Josie Godfrey, Co-Founder and CEO, Realise Advocacy
Nicki K Catterick, Vice President, Global Value and Access Oncology, IPSEN
Eirini Palaka, Vice President, Global Value & Access, Rare Disease, IPSEN
Robert Mitchell-Thain, CEO, PBC Foundation
- What are the implications of the new EU HTA procedure?
- What to expect from Joint Scientific Consultations and Joint Clinical Assessments?
- How can companies best prepare for JCA, starting 12 January 2025?
Matias Olsen, Senior Manager, Public Affairs & Policy, EUCOPE
- Access to innovative medicines remains a key issue worldwide
- Limitations of the some of the initiatives to address this such as the EUnetHTA JCA and the expected change in legislation in Europe
- How can pharmaceutical companies and health authorities work together to bridge the gap
Moderator:
Stefano Romanelli, Senior Government Affairs, EUCOPE
Panellists:
Sandeep Kiri, Global Head of Health Economics and HTA Evidence, UCB
Matthias Heck, Sr Director, International TA Policy Strategy, Alexion Pharmaceuticals
James Levine, President, Ipsen Foundation
- Plasma-derived medicines (PDMPs) are essential for some 300,000 patients across the EU who rely on these therapies every day to treat a variety of rare, chronic, and life-threatening conditions. Without these treatments, many patients would have a substantially diminished quality of life, and some may
not survive. - PDMPs are a finite resource because the manufacture of these medicines is dependent on the amounts of human plasma collected.
- Using the AIFA CTS Innovation Algorithm and the WHO Framework for Appropriate Medical Use, a broad range of Key Opinion leaders, in the field of immunology, neurology, rheumatology and dermatology, debated about the appropriate use of Immunoglobulins for their patients. The discussion
was concluded in a Green Paper developed by Vintura.
Maarten Van Baelen, Executive Director, Plasma Protein Therapeutics Association
- What is happening in Europe vs US
- Are we seeing an increase in Innovative contracting
- Where does a value-based contract make sense
Simon Farrow, Global VP of Sales and Business Development, LYFEGEN
- Looking beyond market access to patient access
- What patients can bring to access and how to support them
- Collaborating for success in access
Josie Godfrey, Co-Founder and CEO, Realise Advocacy
- Rare Diseases landscape
- Acquisition Trends
- High failure rate
- De-risking challenges
- Identifiable Factors Contribute to Risk
- Re-Defining Success
James Levine, President, Ipsen Foundation
- Why and how enterprises should invest into early HEOR and pathway improvement?
- How AI can impact early HEOR and pathway improvement evaluations: key benefits to the life sciences and medtech industry
- Case examples from the UK: chronic liver disease, Heart failure and/or Haemophilia
Dr Samir Khan, Founder and Managing Director, Lighthouse Innovations Ltd
- As innovation brings cancer drugs & curative medicines to the forefront of healthcare systems, how are payers affording to pay for this innovation ?
- what are the new determinants of value in healthcare, and the geopolitical drivers for value based agreements & innovative contracting ?
- If the drugs dont work – I want my money back! – access into a global tracker of over 700 innovative contracts from around the globe
- Who’s shifting the paradigm – adoption curves for those manufacturers leading the way in capabilities for innovative contracting
Moderator:
Esther Nzenza, Founder and CEO, Decisive Consulting Ltd.
Panellist:
Hazel Dawson, Market Access Director, UK & Ireland, Alexion Pharma UK
Dr Samir Khan, Founder and Managing Director, Lighthouse Innovations Ltd
Janek Hendrich, Value Strategies Lead – Oncology, AstraZeneca
- The importance of making MA the core of the company
- Bridge between pre-launch strategy and post-launch
- International Drug Price Indicator Guide WHO
- Increasing collaboration between EU countries
- Frontiers in Health Care
- What will the future bring?
Moderator:
Esther Nzenza, Founder and CEO, Decisive Consulting Ltd.
Panelists:
Josie Godfrey, Co-Founder and CEO, Realise Advocacy Robert Mitchell-Thain, CEO, PBC Foundation
Josie Godfrey, Co-Founder and CEO, Realise Advocacy
